Acumen Pharmaceuticals, Inc.

Listed Company

ABOSCIK 0001576885NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-121.33M

Total Assets

$122.83M

Equity

$70.43M

Shares Out

72.21M

Op. Cash Flow

$-115.54M

Business

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a targeted immunotherapy approach for Alzheimer’s disease focused on soluble amyloid‑beta oligomers (AßOs). Its main product candidate is sabirnetug (ACU193), a recombinant humanized IgG2 monoclonal antibody designed to selectively bind and neutralize AßOs to slow disease progression in early AD. The company’s activities center on clinical development (Phase 1 and Phase 2 trials), nonclinical research, and partnerships for formulation and manufacturing. It conducts trials and pursues collaborations and licensing globally, sourcing manufacturing through contract manufacturers and commercial partners.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	105	94	42	32	12
General and administrative	19	20	19	13	7
Total operating expenses	124	114	61	45	20
Loss from operations	−124	−114	−61	−45	−20
Interest income	7	14	11	—	—
Interest expense	−4	−4	−581,000	—	—
Change in fair value of embedded derivatives	−460,000	2	−1	0	—
Other expense, net	−266,000	−151,000	−83,000	−11,000	51,000
Total other income	2	12	9	2	−81
Net loss	−121	−102	−52	−43	−101
Unrealized gain (loss) on marketable securities	131,000	−360,000	1	−520,000	−231,000
Comprehensive loss	−121	−103	−51	−43	−101
Net loss per common share, basic (in dollars per share)	−2	−1.71	−1.08	−1.06	−5.02
Net loss per common share, diluted (in dollars per share)	−2	−1.71	−1.08	−1.06	−5.02
Weighted-average shares outstanding, basic (in shares)	61	60	49	41	20
Weighted-average shares outstanding diluted (in shares)	61	60	49	41	20

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	54	36	67	130	122
Marketable securities, short-term	63	136	177	48	72
Prepaid expenses and other current assets	5	7	3	3	4
Total current assets	122	178	247	180	199
Marketable securities, long-term	0	60	63	16	32
Restricted cash	231,000	232,000	—	—	—
Other assets, long-term	350,000	486,000	724,000	151,000	14,000
Total assets	123	239	310	197	230
Accounts payable	554,000	6	1	2	1
Accrued clinical trial expenses	11	15	4	3	147,000
Accrued expenses and other current liabilities	10	7	6	3	—
Debt, short-term	9	0	—	—	—
Total current liabilities	30	28	13	8	5
Debt, long-term	22	29	30	0	—
Other liabilities, long-term	0	150,000	284,000	—	—
Total liabilities	52	57	43	8	5
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively	6,000	6,000	6,000	4,000	4,000
Additional paid-in capital	517	507	489	360	353
Accumulated deficit	−447	−325	−223	−170	−128
Accumulated other comprehensive income (loss)	83,000	−48,000	312,000	−751,000	—
Total stockholders equity	70	182	267	189	225
Total liabilities and stockholders equity	123	239	310	197	230

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	58,000	63,000	61,000	32,000	4,000
Stock-based compensation expense	10	10	6	3	922,000
Amortization of premiums and accretion of discounts on marketable securities, net	−809,000	−5	−3	487,000	155,000
Amortization of right-of-use asset	126,000	115,000	123,000	137,000	0
Realized gain on marketable securities	−59,000	−97,000	−11,000	0	—
Noncash interest expense	1	1	145,000	0	—
Other noncash expense	0	232,000	0	0	109,000
Prepaid expenses and other current assets	1	−4	−369,000	2	−4
Other long-term assets	40,000	74,000	−70,000	−137,000	−14,000
Accounts payable	−5	4	−261,000	552,000	557,000
Accrued clinical trial expenses	−5	11	2	3	147,000
Accrued expenses and other liabilities	3	32,000	3	−562,000	3
Finance lease liability	0	−23,000	17,000	0	—
Net cash used in operating activities	−116	−86	−43	−35	−18
Purchases of marketable securities	−38	−171	−251	−42	−104
Proceeds from maturities and sales of marketable securities	172	219	79	81	0
Purchases of property and equipment	−88,000	−16,000	−21,000	−161,000	−40,000
Net cash provided by investing activities	134	48	−172	39	−104
Proceeds from issuance of common stock, net of issuance costs	0	8	122	4	169
Proceeds from exercise of stock options	39,000	0	325,000	115,000	15,000
Payment for financing lease	0	−739,000	0	—	—
Payments for deferred offering costs	0	−230,000	0	—	—
Repurchase of common shares to pay employee withholding taxes	−73,000	−41,000	0	—	—
Net cash (used in) provided by financing activities	−34,000	7	152	4	200
Net change in cash and cash equivalents and restricted cash	18	−31	−63	8	78
Cash paid for income taxes	0	0	0	0	0
Cash paid for interest	3	3	169,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro